European university hospitals referred 9613 blood isolates for in vitro testing against 120 antimicrobial agents. Escherichia coli, Staphylococcus aureus, coagulase-negative Staphylococcus, Pseudomonas aeruginosa, and Klebsiella pneumoniae were the 5 most frequent isolates and accounted for two-thirds of all referrals, with minor regional variation. Of these, ∼0.36% of E. coli and 16.7% of K. pneumoniae isolates proved to be potential extended-spectrum blactamase producers, and their incidence clearly varied regionally. Quinolone resistance was detected among gram-negative species; in particular, P. aeruginosa and Acinetobacter species. Considerable regional variation was observed in the incidences of methicillin resistance in S. aureus and penicillin resistance in Streptococcus pneumoniae. The incidence of vancomycin resistance in enterococci was relatively low overall and primarily associated with Enterococcus faecium. However, extrapolation of these data to smaller and nonteaching hospitals should be undertaken with caution, since resistance rates may be lower in these facilities.
lactamases (ESBLs) [12, 13] , but also among glucose nonfermentative bacteria such as Pseudomonas species [14] , Acinetobacter species [15] , Stenotrophomonas maltophilia, and Burkholderia species [16] . Similar changes have been observed in the antibiotic susceptibility of gram-positive organisms [17, 18] . The widespread emergence of resistance, for example, in methicillin-resistant staphylococci [17] , penicillin-resistant Streptococcus pneumoniae [19] , and glycopeptide-resistant enterococci (GRE) [20] has an impact on our ability to effectively treat patients empirically.
The changing spectrum of microbial pathogens within the hospital environment and the widespread emergence of microbial resistance to antibiotic drugs emphasize the need not only for local sureveillance programs but also for national and international programs to monitor the prevalence of resistance [21] . Resistance data derived from surveillance studies can provide crucial information for the understanding of the spread of antibiotic resistance and encourage the prudent use of antibiotics, a key component in controlling the emergence and spread of resistance. The SENTRY antimicrobial surveillance program is an international surveillance program that monitors the frequency of occurence of pathogens and centrally tests the susceptibility of all isolates at reference centers based in the Netherlands, the United States, and Australia [22] .
In this report, we describe the frequency of isolation of clinically significant bacteria from blood during the period April 1997 through January 1999 and describe the susceptibility of these organisms to a range of antibiotic compounds. 
Materials and Methods
SENTRY antimicrobial surveillance program design. SENTRY was established to monitor the frequency of occurrence and antimicrobial susceptibility of both nosocomial and communityacquired bacterial pathogens via an international network of sentinel hospitals, distributed roughly equally by size and location. Referral of the first 20 consecutive blood culture isolates judged to be clinically significant by local criteria each calendar month were requested from each participating hospital. Only 1 isolate was permitted per patient. The species of each isolate was determined at the source, according to the routine methodology used at the referring hospital, and sent to our institute by use of Amies charcoal medium transport swabs (Becton-Dickson, Franklin Lakes, NJ). Upon receipt, isolates were subcultured onto blood agar to ensure purity. Isolate identity was confirmed, if necessary, by use of a Vitek system (Bio-Mérieux, Lyon, France). Isolates were stored by use of the Microbank system (Oxoid, Basingstoke, UK) at Ϫ70ЊC until testing.
Antimicrobial agents and susceptibility testing. MICs of a range of antibiotics were determined by use of a broth microdilution method and standard methods defined by the National Committee for Clinical Laboratory Standards (NCCLS) [23] . Cationadjusted Mueller-Hinton broth was used as the growth medium throughout the study (Dade International, Sacramento, CA, or Sensitre, Westlake, OH). The final bacterial inoculum concentration used was cfu/mL. Trays were incubated for 20-24 5 ∼ 5 ϫ 10 h at 35ЊC in ambient air before determination of MIC values. NCCLS breakpoints were used to interpret MIC data. Broth microdilution plates were designed specifically for the SENTRY study and contained extended range dilutions of the following antibiotics, depending on whether an isolate was gram-positive, gram-negative, or fastidious: ampicillin, oxacillin, penicillin, piperacillin, ticarcillin, amoxicillin/clavulanate, ticarcillin/clavulanate, piperacillin/tazobactam, cefazolin, cefuroxime, cefoxitin, ceftriaxone, ceftazidime, cefepime, aztreonam, imipenem, meropenem, amikacin, gentamicin, tobramycin, streptomycin, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, gatifloxacin, trovafloxacin, erythromycin, clindamycin, quinupristin/dalfopristin, chloramphenicol, rifampin, tetracycline, vancomycin, and trimethoprim-sulfamethoxazole. Appropriate quality control was performed by use of E. coli ATCC 25922, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853, S. pneumoniae ATCC 49619, and Enterococcus faecalis ATCC 29212. NCCLS-defined breakpoints were used to interpret MIC data in subsequent analyses.
Results

Frequency of occurrence of bloodstream isolates.
During the study period, 9613 consecutive nonrepeat blood isolates were referred by the 24 hospitals for susceptibility testing. A rank order of the 20 most frequently encountered species is shown in table 1. These species represent 198% of all blood isolates referred during the study period. Most referring centers had a similar rank order of pathogens, with E. coli, S. aureus, and coagulase-negative Staphylococcus invariably comprising the top 3. Antimicrobial susceptibility is discussed with respect to the 12 most common species.
Antimicrobial susceptibility of the most common gram-negative pathogens. The antimicrobial susceptibility of the most frequently encountered gram-negative isolates is shown in table 2. The carbapenems were the most active antibiotic against E. coli, Klebsiella pneumoniae, and Enterobacter species, with between 90% and 100% of all isolates from all centers being susceptible. Piperacillin/tazobactam was the most active of the penicillin-derived compounds, with total susceptibility per center ranging from 90% to 100% for E. coli, except in Turkey and Israel, where susceptibility ranged from 61% to 73%. Susceptibility of K. pneumoniae ranged from 33% to 100%. Only the Enterobacter species fell below an average of 90% susceptibility; organism susceptibilities from individual centers ranged from as low as 0% in Italy to 100% in the Netherlands. At least 94.7% of all gram-negative Enterobacteriaceae isolates were susceptible to cefepime. E. coli and K. pneumoniae with reduced susceptibility to cefepime were isolated in various countries without a clear geographic distribution. Meropenem was the most active drug against P. aeruginosa and Acinetobacter species. Piperacillin/tazobactam was the most active penicillin compound, although it inhibited only 57.1% of Acinetobacter isolates. Of the cephalosporins tested, ceftazidime and cefepime were the most active, although only 51.4% and 62.8%, respectively, of the Acinetobacter isolates remained susceptible to them. By using resistance to ceftazidime, ceftriaxone, or aztreonam with susceptibility to cefoxitin as markers for the potential presence of ESBLs, we found that 0.36% of the E. coli and 16.7% of the K. pneumoniae isolates were potential carriers of these enzymes.
Distinct regional variations were detected in the incidences of these ESBL-producing phenotypes. Only 6 of the 24 hospitals (located in Austria, France, Italy, Spain, United Kingdom, and Netherlands) referred E. coli that were potential ESBL producers. All centers, with the exception of the centers from Linz, Brussels, Paris (I), Dü sseldorf, Utrecht, Warsaw, Madrid, Bar- celona, and Lausanne referred isolates that were potential ESBL producers.
Of the non-b-lactam compounds, the aminoglycoside compounds (in particular, amikacin) provided the best coverage against Enterobacteriaceae, with at least 93.4% of isolates fully susceptible. Only 8 centers showed E. coli with a reduced susceptibility to the agent, but no clear geographic distribution was apparent, and the same observation was made for K. pneumoniae (data not shown). Levofloxacin was the most active quinolone with defined NCCLS breakpoints [23] , although overall only 87.1% of Enterobacter species isolates were susceptible. Of the aminoglycosides, amikacin showed the greatest activity against P. aeruginosa and Acinetobacter species, although overall only 59.1% of Acinetobacter isolates were susceptible, compared with 89.9% of P. aeruginosa isolates. Quinolones showed poor activity against the nonfermentors. Only 74.9% and 54.7% of P. aeruginosa and Acinetobacter isolates, respectively, showed in vitro susceptibility. Similar rates of resistance were seen throughout the different European centers. Tetracycline demonstrated poor activity against gram-negative isolates from all centers.
Antimicrobial susceptibility of the most common gram-positive pathogens. S. aureus and coagulase-negative Staphylococcus were the 2 most common gram-positive species isolated from participant hospitals during the study period. Susceptibility to oxacillin differed significantly among staphylococci, with an average of 23.7% of S. aureus isolates and 59.1% of coagulasenegative Staphylococcus isolates showing resistance to oxacillin and, by inference, cross-resistance to all other b-lactam compounds. Methicillin-resistant Staphylococcus aureus (MRSA) was sent from every hospital included in this surveillance study, except for the center in the Netherlands. Incidences, however, showed a dramatic range: !5% in Swiss, German, and 1 Spanish hospital; ∼10% in the Austrian and 1 Spanish center; ∼20%-30% in centers in France, Poland, 1 in Turkey, and 1 Spanish hospital; 30%-40% in Portugal, Greece, Belgium, and 1 Italian and 1 Turkish center; and 150% in a second Italian hospital. Imipenem, piperacillin/tazobactam, and cefepime were predictably highly active against oxacillin-susceptible isolates. Rates of oxacillin resistance among coagulase-negative Staphylococcus isolates from different countries remained relatively uniform, independent of the rate of oxacillin resistance among S. aureus.
With regard to non-b-lactam compounds, all staphylococci remained fully susceptible to vancomycin. They showed similar susceptibility to teicoplanin, except for a few methicillin-resistant coagulase-negative Staphylococcus isolates that showed intermediate resistance. Few oxacillin-resistant staphylococci were susceptible to ciprofloxacin, whereas only 89.6% of the oxacillin-susceptible S. aureus were susceptible, and 86% of the coagulase-negative Staphylococcus isolates. Reduced susceptibility to all other drugs tested was higher among methicillin- Next to the staphylococci, the most common gram-positive bloodstream isolates were Enterococcus species, S. pneumoniae, and viridans streptococci. The activity of different antimicrobial agents against Enterococcus species, viridans streptococci, and Streptococcus species are shown in tables 4 and 5. Penicillin and carbapenem compounds maintained good activity against E. faecalis isolates, whereas no b-lactam agent showed sufficient in vitro activity against Enterococcus faecium isolates to be considered as a therapeutic agent (data not shown). Eleven percent of E. faecium isolates and 1.2% of E. faecalis isolates showed reduced susceptibility to vancomycin and cross-resistance to teicoplanin. Reduced activity of all non-b-lactam drugs was associated with decreased penicillin susceptibility. Similarly, only an average of 60.8% of viridans streptococci were susceptible to penicillin. The percentage susceptible varied from center to center. The lowest rates of resistance were recorded in some hospitals in France, Germany, Poland, Spain, and the United Kingdom (all near 100% susceptible), whereas high rates of resistance were recorded in other centers in France, Greece, and Spain (ranging from 0% to ∼50% susceptible). A total of 30% of the viridans streptococci showed reduced susceptibility to erythromycin (range between centers, 50%-100% susceptible). Clindamycin showed better activity (84% susceptibility).
Overall, 31.5% of S. pneumoniae blood isolates showed reduced susceptibility to penicillin; nearly 7% were fully resistant. Isolates of S. pneumoniae with reduced penicillin susceptibility were primarily associated with referring hospitals in France, Germany, Spain, Switzerland, and the United Kingdom. Onehalf to one-third of the centers demonstrated reduced susceptibility to penicillin, although the total numbers of referred isolates from each center are too low to refer to percentage values (the average being about 10 isolates referred per center). In total, only 4 isolates showed high-level resistance, 2 from France and 2 from Spain. Other b-lactam compounds only retained in vitro activity against penicillin-susceptible isolates. All quinolone compounds showed poor activity against all the enterococci tested, although they all showed potent activity against most S. pneumoniae and viridans streptococci from all referring centers.
Discussion
During the last decade, the decreasing susceptibility of commonly encountered bacterial pathogens has attracted much attention. Surveillance of bacterial antimicrobial resistance is the cornerstone of our attempts to understand the dynamics of decreasing susceptibility to antibiotics in both hospital and community-acquired bacterial pathogens. Several national studies in the United States, such as Surveillance and Control of Pathogens of Epidemiological Importance (SCOPE), Intensive Care Antimicrobial Resistance Epidemiology (ICARE), and NNIS [24] [25] [26] , have provided a range of resistance and associated data for a variety of bacterial pathogens, such that, at least in the United States, relatively good national susceptibility data are available. Our knowledge of the extent of bacterial drug resistance in Europe is more fragmented. The SEN-TRY study is designed to provide a broader picture of resistance across the European continent, including data on the susceptibility to a wide range of antibiotics of all bacterial species commonly encountered. All strains referred to the study are centrally tested by standardized methods. The frequency of occurrence of isolates shown in table 1 demonstrates the role that E. coli and S. aureus play in human infectious disease; together these 2 species are responsible for more than one-third of all bacteremias in participating hospitals. This is consistent with SENTRY-USA data [22] and also reflects data from other US studies [12, 27] .
Resistance among gram-negative organisms to narrow-spectrum b-lactam agents, particularly for the nonfermentors but also for the commonly encountered Enterobacteriaceae, will lead to an increasing need for reliance on broad-spectrum compounds, such as penicillin derivatives combined with an inhibitor compound, third-or of fourth-generation cephalosporins, or carbapenems. ESBL production appears still to be rare among E. coli isolated from bloodstream infections, in contrast to K. pneumoniae isolates from bloodstream infections, among which ESBL production appears to reach 9%. Continued surveillance will be required to monitor the spread of ESBL-carrying plasmids and/ or bacteria harboring these enzymes. However, ESBL production is clearly often a local problem, as demonstrated, for example, by the fact that ESBL production was detected in only some of the French and Spanish participant hospitals.
Quinolone resistance among gram-negative species is an increasing problem, given that the percentage of resistant isolates for the Enterobacteriaceae is approaching 10% of the population. Striking is the high efficacy of amikacin against many of the gram-negative species, which demonstrates the relatively low prevalence of amikacin-modifying enzymes in these Enterobacteriaceae in participant hospitals. P. aeruginosa, but especially Acinetobacter species, demonstrated high levels of resistance against most antibiotics tested. For Acinetobacter species, the levels of resistance were lowest for imipenem and meropenem. Recent reports of acquired carbapenemase activity in this species and among species of Enterobacteriaceae highlight the need to carefully monitor carbapenem susceptibility [28] [29] [30] .
Methicillin resistance in S. aureus averaged 24% across Europe but with considerable regional variation, partly confirming the findings of a previous review [25] . Again, some interregional variations are apparent, since the incidence of MRSA in 2 of the Spanish hospitals was 5%-14%, whereas it was as high as 27% in another hospital. In contrast to a recent report [31] , all S. aureus isolates remained fully susceptible to vancomycin, showing that isolates with reduced susceptibility still remain rare local events [32] .
Unlike in the United States, the incidence of GRE remains relatively low in Europe [33] . Overall, 1.2% of E. faecalis isolates showed resistance to vancomycin, compared with 11.1% of E. faecium isolates. Careful surveillance, including appropriate speciation of Enterococcus isolates, will be necessary to monitor interspecific transfer of vancomycin resistance-encoding genes in the future, in order to determine whether glycopeptide resistance will also become a problem in E. faecalis isolates.
Susceptibility remains high to the newer broad-spectrum agents, such as penicillin-inhibitor combinations, carbapenems, third-and fourth-generation cephalosporins, and quinolone compounds.
Data derived from this study show that with a few exceptions (e.g., enterococcal isolates resistant to vancomycin) resistance to some antibiotics for a number of species implicated in bac- teremia has reached worrisome levels. The levels of resistance may vary across Europe and even within countries, which would suggest that resistance may be largely a nosocomial problem. Nevertheless, the data from this study may not be extrapolated to smaller hospitals. The majority of isolates in this study were from patients in teaching hospitals, and no differentiation could be made between nosocomial and communityacquired infections. If compared with data from smaller hospitals, these factors may exaggerate the rates of resistance and may lead broad-spectrum antibiotics to be overused. Our data underscore the need to be vigilant and to continue antimicrobial resistance surveillance programs, which can provide valuable insight into resistance trends, but antibiotic policy should ultimately be based on the local situation. In the future, much can be learned from comparing infection control practices and antibiotic usage in hospitals with low or high resistance rates.
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